Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer

Acta Oncologica

Volumn 53, Issue 2, 2014, Pages 174-185

  Ejlertsen, Bent ^a   Jensen, Maj Britt ^a   Mouridsen, Henning T ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ALGORITHM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; DATA BASE; DISEASE ASSOCIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION RESEARCH; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSTIC STANDARD MORTALITY RATE INDEX; RECURRENCE FREE SURVIVAL; RISK FACTOR; ADJUVANT THERAPY; BREAST CANCER; CANCER RECURRENCE; CANCER SIZE; CONTROLLED STUDY; FOLLOW UP; LYMPH VESSEL METASTASIS; MORTALITY; PATIENT COMPLIANCE;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84892164441     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.850738     Document Type: Article

References (25)

1. , G odwin J, G ray R , P an HC, C larke M , et al . Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials . Lancet 2012 ; 379 : 432-44
2. Harlan LC, C legg LX, A brams J, S tevens JL, B allard-B arbash R . Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000 . J Clin Oncol 2006 ; 24 : 872-7
3. Haybittle JL, B lamey RW , E lston CW, J ohnson J , D oyle PJ , Campbell FC , et al . A prognostic index in primary breast cancer . Br J Cancer 1982 ; 45 : 361-6
4. Balslev I , A xelsson C K, Z edeler K , R asmussen BB, Carstensen B , Mouridsen HT . The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) . Breast Cancer Res Treat 1994 ; 32 : 281-90
5. Ravdin PM , S iminoff LA , D avis GJ , M ercer MB , H ewlett J, Gerson N , et al . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980-91
6. Azim H A , M ichiels S , Z agouri F , D elaloge S , F ilipits M , Namer M , et al . Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement . Ann Oncol 2013 ; 24 : 647-54
7. Lambert P C , D ickman PW , N elson C P , R oyston P . E stimating the crude probability of death due to cancer and other causes using relative survival models . Stat Med 2010 ; 29 : 885-95
8. Moller S , J ensen MB, E jlertsen B, B jerre KD , L arsen M , Hansen HB , et al . The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years ' experience and future promise . Acta Oncol 2008 ; 47 : 506-24
9. Ejlertsen B, J ensen MB , R ank F , R asmussen BB, Christiansen P , Kroman N , et al . Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer . J Natl Cancer Inst 2009 ; 101 : 729-35
10. Schemper M , S mith TL . A note on quantifying follow-up in studies of failure time . Control Clin Trials 1996 ; 17 : 343-6
11. Lazar A A , C ole BF, B onetti M , G elber RD . E valuation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: Subpopulation treatment effect pattern plot . J Clin Oncol 2010 ; 28 : 4539-44
12. Sauerbrei W, R oyston P , B ojar H, S chmoor C, Schumacher M . Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG) . Br J Cancer 1999 ; 79 : 1752-60
13. Royston P , S auerbrei W . A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials . Stat Med 2004 ; 23 : 2509-25
14. Ejlertsen B, M ouridsen HT , J ensen MB , A ndersen J, Cold S , Edlund P , et al . Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer . Eur J Cancer 2007 ; 43 : 877-84
15. Lash TL , F ox M P , W estrup J L, F ink AK , S illiman R A . Adherence to tamoxifen over the fi ve-year course . Breast Cancer Res Treat 2006 ; 99 : 215-20
16. Statistics Denmark. S tatBankDenmark.http://www.statistikbanken.dk/
17. Regan M M , N even P , G iobbie-Hurder A , G oldhirsch A , Ejlertsen B , Mauriac L , et al . Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up . Lancet Oncol 2011 ; 12 : 1101-8
18. Forbes JF, C uzick J, B uzdar A , H owell A , T obias JS , Baum M . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial . Lancet Oncol 2008 ; 9 : 45-53
19. McCowan C , S hearer J , D onnan P T , D ewar J A , C rilly M , Thompson AM , et al . Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer . Br J Cancer 2008 ; 99 : 1763-8
20. Guth U , H uang DJ , S chotzau A , Z anetti-Dallenbach R , Holzgreve W , Bitzer J , et al . Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer . Br J Cancer 2008 ; 99 : 428-33
21. Owusu C, B uist D S , F ield TS , L ash TL , T hwin S S , Geiger AM , et al . Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer . J Clin Oncol 2008 ; 26 : 549-55
22. Baselga J, C ampone M , P iccart M , B urris HA , I II , R ugo HS , Sahmoud T , et al . Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer . N Engl J Med 2012 ; 366 : 520-9
23. Clarke M , C ollins R , D arby S , D avies C , E lphinstone P , Evans E , et al . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials . Lancet 2005 ; 366 : 2087-106
24. Mell L K, J eong J H, N ichols M A , P olite B N , Weichselbaum RR , Chmura SJ . Predictors of competing mortality in early breast cancer . Cancer 2010 ; 116 : 5365-73
25. Nielsen TO , P arker JS , L eung S , V oduc D , E bbert M , V ickery T , et al . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer . Clin Cancer Res 2010 ; 16 : 5222-32 .